Thu. 11 Apr 2024, 7:09am ET
Benzinga
Biotech, News, Health Care, General
Key findings reported in the study publication regarding fosgonimeton in preclinical models of Alzheimer's disease include:
- In primary rat cortical neurons challenged with Aβ, fosgonimeton treatment improved neuronal survival, protected neurite networks, and reduced tau hyperphosphorylation following Aβ injury.
- Fosgonimeton attenuated Aβ-induced mitochondrial stress and apoptotic signaling.
- Fosgonimeton enhanced activation of pro-survival effectors extracellular signal-regulated kinase (ERK) and protein kinase B (AKT). It also reduced activity of glycogen synthase kinase 3 beta (GSK3β), one of the main kinases involved in tau hyperphosphorylation.
- Fosgonimeton mitigated Aβ-induced deficits in Unc-like kinase 1 (ULK1) and Beclin-1 expression, suggesting a potential effect on autophagy.
- Fosgonimeton improved cognitive performance in an Aβ rat model of Alzheimer's disease.